Outcomes in CMV⁺ treated with letermovir. (A) Cumulative incidence in csCMVi landmarked from the date of transplantation in patients with seropositive CMV treated with letermovir and not treated with letermovir. CMV reactivation was not seen in patients without CMV in this cohort. (B-D) Cumulative incidence of csCMVi in patients treated with letermovir ≥14 weeks (n = 80) landmarked from the time of letermovir withdrawal: (B) entire cohort; (C) patients are grouped based on time of discontinuation of letermovir; and (D) patients are group based on IgG level before letermovir discontinuation (<650 vs ≥650 mg/dL).